Zentalis Pharmaceuticals Inc

NASDAQ:ZNTLUnited States

Nov 13, 2024

Show headlines and story abstract

• Zentalis Pharmaceuticals Appoints Julie Eastland as CEO, from 8:56AM ET on Wednesday Nov 13, 2024 by MT Newswires

  8:56AM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: MRK, ZNTL
  08:56 AM EST, 11/13/2024 (MT Newswires) -- Zentalis Pharmaceuticals (ZNTL) said Wednesday it appointed Julie Eastland to succeed Kimberly Blackwell as chief executive officer. Blackwell will remain as a strategic advisor to the board of directors, t...

• DJ Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen, from 8:22AM ET on Wednesday Nov 13, 2024 by Dow Jones

  8:22AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: ZNTL
  
  By Denny Jacob
  
  Zentalis Pharmaceuticals made changes to its leadership as part of an effort to support the company's plans for studies for azenosertib, its lead product candidate.
  

• Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib, from 8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones

  8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: ZNTL
  
  This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the registrational studies of azenosertib; clinical development activities for azenosertib and data that could support accelerated approval; the potential of azenosertib; the Company's plans to advance azenosertib, including initiating and completing studies to obtain approval; the Company's plans to operate in a capital efficient manner in order to maximize shareholder value; the Company's plans for an investor event and the timing thereof; and expected contributions from team members. The terms "believe," "goal," "intend," "look forward," "plan," "potential," and "will" and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our plans, including the costs thereof, of development of any diagnostic tools; our substantial dependence on the success of our lead product candidate, azenosertib; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption "Risk Factors" in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
  

• Press Release: Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib, from 8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones

  8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: ZNTL